Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer

NCT00597597 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped not enough patients enrolled

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Erlotinib

Sponsor

Rush University Medical Center